Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Forma Therapeutics Holdings Inc.
Headquarters: Watertown, MA, United States of America
Website: N/A
Year Founded: 2007
Status: Acquired
BioCentury | Apr 11, 2023
Management Tracks
Legend hires Koneru as CMO
Plus: Erasca promotes Morris, Lovejoy and updates from Poseida, Mithra, Tune, Cellarity and more
BioCentury | Mar 3, 2023
Finance
March 2 Quick Takes: MorphoSys laying off staff, ending preclinical work
Plus: Flamingo teaming up with Dynacure and updates from Debiopharm, Aldeyra, Checkpoint and more
BioCentury | Sep 1, 2022
Deals
$1.1B Forma buyout gives Novo advanced sickle cell asset with potential for accelerated approval
Latest takeout in SCD is the culmination of Forma’s realignment around its internal pipeline
BioCentury | Aug 3, 2022
Finance
Aug. 2 Quick Takes: Yescarta label expansion buoys Gilead’s 2Q22 sales
Plus Megaround for Sironax, and updates from Eleven, Roche, Axcella, Phathom, and more
BioCentury | Jun 30, 2022
Management Tracks
FDA names Bumpus chief scientist, Marston CMO
Plus Beyer becomes CEO at Kures, and updates from NGM, Apexigen, Achilles and more
BioCentury | Apr 6, 2022
Management Tracks
Sabatini out at MIT
Plus Avidity expands role of MacLean and updates from Exscientia, eFFECTOR, Sofinnova and more
BioCentury | Dec 1, 2021
Management Tracks
Grauer becomes CMO at Federation Bio
Plus: LabGenius, 23andMe, Vifor, Immunovia, Forma and more
BioCentury | Oct 17, 2020
Finance
Novartis Venture Fund’s move to earlier, riskier bets starting to pay off
NVF’s 2020 liquidity events could be a sign that its strategic shift and new team are moving in the right direction
BioCentury | Jun 20, 2020
Finance
Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum
Beijing-based Genetron debuts with $1.4B valuation as quartet of biotechs price offerings
BioCentury | Jun 2, 2020
Finance
CAR T play Legend looks to lead trio of biotechs onto NASDAQ
Pliant, Lantern also hope to price IPOs this week
Items per page:
1 - 10 of 10